---
title: "Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287223836.md"
description: "Fate Therapeutics, Inc. (NASDAQ: FATE) announced it will present data on its off-the-shelf CAR T-cell therapy pipeline at the 2026 ASCO Annual Meeting in Chicago from May 29 to June 2, and the EULAR Annual Meeting in London from June 3 to June 6, focusing on iPSC-derived immunotherapies for cancer and autoimmune diseases."
datetime: "2026-05-21T12:33:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287223836.md)
  - [en](https://longbridge.com/en/news/287223836.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287223836.md)
---

# Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

On May 21, 2026, Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, revealed plans to showcase data from its off-the-shelf CAR T-cell programs at two upcoming events. The American Society of Cancer Oncology Annual Meeting in Chicago, IL from May 29 to June 2, 2026, and the European Congress of Rheumatology in London, UK from June 3 to June 6, 2026 will host presentations on the company's induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839](https://longbridge.com/en/news/292199195.md)
- [Biotech experts want FDA drug reviews based on science, not politics](https://longbridge.com/en/news/293453841.md)
- [Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences](https://longbridge.com/en/news/282206169.md)